Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) rose 6.6% during trading on Thursday . The company traded as high as $13.30 and last traded at $13.48. Approximately 457,699 shares traded hands during trading, a decline of 66% from the average daily volume of 1,334,590 shares. The stock had previously closed at $12.65.
Analyst Ratings Changes
A number of equities analysts have weighed in on CAPR shares. Cantor Fitzgerald increased their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.50.
View Our Latest Research Report on CAPR
Capricor Therapeutics Stock Down 4.4 %
The company has a 50-day moving average price of $14.34 and a two-hundred day moving average price of $14.12. The stock has a market capitalization of $556.55 million, a P/E ratio of -11.45 and a beta of 4.10.
Institutional Trading of Capricor Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of CAPR. Oppenheimer & Co. Inc. boosted its stake in Capricor Therapeutics by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company's stock valued at $1,040,000 after buying an additional 13,762 shares during the period. The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at about $161,000. FMR LLC purchased a new position in shares of Capricor Therapeutics during the third quarter worth about $370,000. BNP Paribas Financial Markets increased its position in shares of Capricor Therapeutics by 868.7% in the third quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company's stock worth $269,000 after purchasing an additional 15,872 shares during the last quarter. Finally, Fred Alger Management LLC purchased a new stake in Capricor Therapeutics in the third quarter valued at approximately $399,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
